Cargando…

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease

OBJECTIVE: Proline–glycine–proline (PGP) has been shown to have chemotactic effects on neutrophils via CXCR2 in several lung diseases. PGP is derived from collagen by the combined action of matrix metalloproteinase (MMP) 8 and/or MMP9 and prolyl endopeptidase (PE). We investigated the role of PGP in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koelink, Pim J, Overbeek, Saskia A, Braber, Saskia, Morgan, Mary E, Henricks, Paul A J, Roda, Mojtaba Abdul, Verspaget, Hein W, Wolfkamp, Simone C, te Velde, Anje A, Jones, Caleb W, Jackson, Patricia L, Blalock, J Edwin, Sparidans, Rolf W, Kruijtzer, John A W, Garssen, Johan, Folkerts, Gert, Kraneveld, Aletta D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963538/ https://www.ncbi.nlm.nih.gov/pubmed/23525573 http://dx.doi.org/10.1136/gutjnl-2012-303252

Ejemplares similares

Cigarette Smoke-Induced Collagen Destruction; Key to Chronic Neutrophilic Airway Inflammation?
por: Overbeek, Saskia A., et al.
Publicado: (2013)

Correction: Cigarette Smoke-Induced Collagen Destruction; Key to Chronic Neutrophilic Airway Inflammation?
por: Overbeek, Saskia A., et al.
Publicado: (2013)

Cigarette smoke induces β(2)-integrin-dependent neutrophil migration across human endothelium
por: Overbeek, Saskia A, et al.
Publicado: (2011)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

Inflammatory changes in the airways of mice caused by cigarette smoke exposure are only partially reversed after smoking cessation
por: Braber, Saskia, et al.
Publicado: (2010)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
por: Thomas, Pepijn W. A., et al.
Publicado: (2021)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

Delphi consensus survey: the opinions of patients living with refractory ulcerative proctitis and the health care professionals who care for them
por: Kyriacou, Maro, et al.
Publicado: (2023)

Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes
por: Christodoulou, Katja, et al.
Publicado: (2013)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
por: Jongsma, Maria M E, et al.
Publicado: (2022)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis
por: Weisel, Kathy, et al.
Publicado: (2021)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up
por: Lansdorp, Corine A., et al.
Publicado: (2022)

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
por: Jones, Gareth-Rhys, et al.
Publicado: (2019)

School-related experience and performance with inflammatory bowel disease: results from a cross-sectional survey in 675 children and their parents
por: Freckmann, Magdalena, et al.
Publicado: (2018)

Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
por: Din, Shahida, et al.
Publicado: (2020)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Crohn’s disease therapeutic dietary intervention (CD-TDI): study protocol for a randomised controlled trial
por: Raman, Maitreyi, et al.
Publicado: (2022)

Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism
por: Oancea, I, et al.
Publicado: (2017)

Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study
por: Sebastian, Shaji, et al.
Publicado: (2022)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
por: Rutgeerts, Paul J, et al.
Publicado: (2013)

Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease
por: Manon‐Jensen, T., et al.
Publicado: (2021)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial
por: Feagan, B. G., et al.
Publicado: (2016)

Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study
por: Benchimol, Eric I, et al.
Publicado: (2017)

Andrographis paniculata Extract (HMPL-004) for Active Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2013)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Mouse Paneth cell antimicrobial function is independent of Nod2
por: Shanahan, Michael T, et al.
Publicado: (2014)

Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
por: Wang, Ming-Hsi, et al.
Publicado: (2023)

Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease
por: Turcotte, Jean-Francois, et al.
Publicado: (2012)

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands
por: de Bock, Ellen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qga6mi6267lfgl0j721q2f3elk